FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 243 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... June 11, 2019 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 EMA Recommends Extension of Indications for Enzalutamide April 2, 2021 Load more HOT NEWS Can cancer cells communicate? Patient Guide in Colorectal Cancer Now Available in Bulgarian Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each...
